A Retrospective Study on Standard Regimen for Vaccination in Celiac Children


Background: HLA system plays an essential role in the human immune system activity and the expression of some spe-cific HLA antigens could modify the immune response to vaccinations. Celiac Disease is included among the diseases associated to specific HLA profiles, principally characterized by the expression of the HLA DQ2 antigen. Object: Our study was a retrospective study, leaded on a group of celiac children, with the object to evaluate their immunological response to both obligatory and recommended vaccinations in childhood. Materials and methods: It was a retrospec-tive study, including 66 patients affected by celiac disease, between 3 and 15 years of age, and a control group of 50 children of the same age. All patients performed both obligatory and recommended vaccinations as indicated in the Italian standard regimen for vaccinations. The immunologic response to each vaccine was analysed and compared in the two groups. Moreover, authors also studied the immunologic response to vaccines in celiac children comparing patients whose diagnosis was made before 18 months of age with those whose disease was diagnosed after 18 months of age. Results: Our results showed that in celiac patients the immunological response to vaccine is similar to that one found in general population, except for HBV vaccine. Conclusions: the valuation of immunological response to HBV vaccine should be regularly effectuated in celiac children and revaccination should be recommended.

Share and Cite:

S. Leonardi, G. Vitaliti, A. Pratico’, R. Pecoraro and M. Rosa, "A Retrospective Study on Standard Regimen for Vaccination in Celiac Children," World Journal of Vaccines, Vol. 1 No. 2, 2011, pp. 29-32. doi: 10.4236/wjv.2011.12006.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] G. Ada, “Vaccines and Vaccination,” The New England Journal of Medicine, Vol. 345, No. 14, October 2001, pp. 1042-1053. doi:10.1056/NEJMra011223
[2] P. Letontourier, “Vaccination from Theory to Practice,” Presse med, Vol. 34, 2005, p. 547.
[3] C. Wang, J. Tang, W. Song, E. Lobashevsky, C. M. Wilson and R. A. Kaslow, “HLA and Cytokine Gene Polymorphisms are Independently Associated with Responses to Hepatitis B Vaccination,” Hepatology, Vol. 39, No. 4, April 2004, pp. 978-988. doi:10.1002/hep.20142
[4] A. Herman, J. W. Kappler, P. Marrak and A. M. Pullen, “Superantigens: Mechanisms of T-Cellstimulation and Role in Immune Response,” Annual Review of Immunology, Vol. 9, 1991, pp. 745-772. doi:10.1146/annurev.iy.09.040191.003525
[5] K. E. Lundin, H. A. Gjertsen, H. Scott, L. M. Sollid and E. Thorsby, “Function of DQ2 and DQ8 as HLA Susceptibility Molecules in Celiac Disease,” Human immunology, Vol. 41, No. 1, 1994, pp. 24-27. doi:10.1016/0198-8859(94)90079-5
[6] N. P. Radlovi?, et al., “Influence of Early Feeding Practices on Celiac Disease in Infants,” Archives of Disease in Childhood, Vol. 65, 1990, pp. 909-911. doi:10.1136/adc.65.8.909
[7] L. M. Sollid and E. Thorsby, “HLA Susceptibility Genes in Celiac Disease: Genetic Mapping and Role in Pathogenesis,” Gastroenterology, Vol. 105, No. 3, 1993, pp. 910-922
[8] S. Caillat-Zucman, “Molecular Mechanisms of HLA Association with Autoimmune Diseases,” Tissue Antigens, Vol. 73, No. 1, 2009, pp. 1-8. doi:10.1111/j.1399-0039.2008.01167.x
[9] K. Kaukinen, J. Partanen, M. Maki and P. Collin, “HLA-DQ Typing in the Diagnosis of Celiac Disease,” American Journal of Gastroenterology, Vol. 97, 2002, pp. 695-699. doi:10.1111/j.1572-0241.2002.05471.x
[10] E. J. Hoffenberg, T. Mackenzie, K. J. Barriga, G. S. Eisenbarth, F. Bao, J. E. Haas, H. Erlich, T. T. Bugawan, R. J. Sokol, I. Taki, J. M. Norris and M. Rewers, “A Prospective Study of the Incidence of Childhood Celiac Disease,” The Journal of Pediatrics, Vol. 143, No. 3, September 2003, pp. 143:308-314.
[11] S. D. Park, J. Markowitz, M. Pettei, T. Weinstein, C. P. Sison, S. R. Swiss and J. Levine, “Failure to Respond to Hepatitis B Vaccine in Children with Celiac Disease,” Journal of Pediatric Gastroenterology & Nutrition, Vol. 44, No. 4, 2007, pp. 431-435 doi:10.1097/MPG.0b013e3180320654
[12] M. Martinetti, A. De Silvestri, C. Belloni, A. Pasi, C. Tinelli, A. Pistorio, L. Salvaneschi, G. Rondini, M. A. Avanzini and M. Cuccia, “Humoral Response to Recombinant Epatitis B Virus Vaccine at Birth: Role of HLA and Beyond,” Clinical Immunology, Vol. 41, 2000, pp. 1383-1390.
[13] A. Safary and F. Andre, “Over a Decade of Experience with a Yeast Recombinant Hepatitis B Vaccine,” Vaccine, Vol. 18, No. 1-2, August 1999, pp. 57-67. doi:10.1016/S0264-410X(99)00179-6
[14] S. Leonardi, M. Spina, L. Spicuzza, N. Rotolo and M. La Rosa, “Hepatitis B Vaccination Failure in Celiac Disease: Is There a Need to Reassess Current Immunization Strategies?” Vaccine, Vol. 27, No. 43, October 2009, pp. 6030-6033. doi:10.1016/j.vaccine.2009.07.099
[15] A. Godkin, M. Davenport and A. V. Hill, “Molecular Analysis of HLA Class II Associations with Hepatitis B Clearance and Vaccine Non Responsiveness,” Hepatology, Vol. 41, No. 6, June 2005, pp. 1383-1390. doi:10.1002/hep.20716
[16] E. Nemes, E. Lefler, L. Szegedi, A. Kapitány, J. B. Kovács, M. Balogh, K. Szabados, J. Tumpek, S. Sipka and I. R. Korponay-Szabó, “Gluten Intake Interferes with the Humoral Immune Response to Recombinant Hepatitis B Vaccine in Patients With Celiac Disease,” Pediatrics, 121, No. 6, June 2008, pp. 1570-1576 doi:10.1542/peds.2007-2446
[17] K. W. Noh, G. A. Poland and J. A. Murray, “Hepatitis B Vaccine Nonresponse and Celiac Disease,” American Journal of Gastroenterology, Vol. 98, 2003, pp. 2289- 2292. doi:10.1111/j.1572-0241.2003.07701.x
[18] E. Ahishali, G. Boztas, F. Akyuz, D. Ibrisim, S. Poturoglu, B. Pinarbasi, S. Ozdil and Z. Mungan, “Response to Hepatitis B Vaccination in Patients with Celiac Disease,” Digestive Diseases and Sciences, Vol. 53, No. 8, 2008, pp. 2156-2159. doi:10.1007/s10620-007-0128-3

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.